IL-10 rs1800896 Polymorphism: A Risk Factor for Adult Acute Lymphoblastic Leukemia.
IL-10
acute lymphoblastic leukemia
polymorphism
rs1800896
–1082 (A>G)
Journal
Pharmacogenomics and personalized medicine
ISSN: 1178-7066
Titre abrégé: Pharmgenomics Pers Med
Pays: New Zealand
ID NLM: 101514107
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
06
2022
accepted:
30
08
2022
entrez:
19
9
2022
pubmed:
20
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
Single-nucleotide polymorphism (SNP) in the promoter region of the IL-10 gene can increase susceptibility to tumor development. The current study aimed to explore the genotypic frequency of interleukin-10 (IL-10) rs1800896 polymorphism in newly diagnosed adult patients with acute lymphoblastic leukemia (ALL) and validate whether this SNP is a risk factor for adult ALL. This case-control study was based on a subset of newly diagnosed 154 adult patients with ALL recruited from the Radiation and Isotope Center in Khartoum (RICK) and 154 healthy controls from the same geographical area. Genomic DNA was used for the genotyping of rs1800896 polymorphism through allele-specific polymerase chain reaction (PCR) assays. The genotypic frequencies of rs1800896 showed a statistically significant association of AG and AA genotypes with adult ALL ( rs1800896 polymorphism is associated with an increased risk of ALL in adult patients irrespective of the age at diagnosis, gender, and immunophenotype of ALL.
Identifiants
pubmed: 36119849
doi: 10.2147/PGPM.S377356
pii: 377356
pmc: PMC9480578
doi:
Types de publication
Journal Article
Langues
eng
Pagination
809-815Informations de copyright
© 2022 Abdalhabib et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in this work.
Références
J Int Med Res. 2020 Apr;48(4):300060520904863
pubmed: 32349574
Genet Mol Res. 2015 Feb 02;14(1):925-30
pubmed: 25730030
Pediatr Blood Cancer. 2015 Jan;62(1):72-9
pubmed: 25263239
Asian Pac J Cancer Prev. 2013;14(4):2439-42
pubmed: 23725154
In Vivo. 2016 May-Jun;30(3):265-9
pubmed: 27107085
Cancers (Basel). 2020 Feb 07;12(2):
pubmed: 32046104
J Nutr. 2007 Jan;137(1 Suppl):194S-199S
pubmed: 17182825
Cancer Med. 2019 Sep;8(12):5492-5506
pubmed: 31373163
Clin Exp Immunol. 2013 May;172(2):263-79
pubmed: 23574323
Cancer Sci. 2022 Jan;113(1):41-52
pubmed: 34716967
Leuk Res Treatment. 2012;2012:692348
pubmed: 23213548
Immunity. 2019 Apr 16;50(4):871-891
pubmed: 30995504
Lancet. 2020 Apr 4;395(10230):1146-1162
pubmed: 32247396
Virology. 1994 May 1;200(2):724-32
pubmed: 8178456
Eur J Endocrinol. 2015 Apr;172(4):403-13
pubmed: 25583906
Int J Mol Sci. 2017 May 11;18(5):
pubmed: 28492497
Blood Cells Mol Dis. 2015 Aug;55(2):168-72
pubmed: 26142334
Glob Med Genet. 2022 Feb 25;9(2):129-140
pubmed: 35707782
Cancer Biol Ther. 2020 Apr 2;21(4):372-378
pubmed: 31910710
Int J Cancer. 2001 Dec 15;94(6):792-4
pubmed: 11745479
Ann Oncol. 1999 Apr;10(4):433-40
pubmed: 10370786
J Clin Oncol. 2016 Oct 10;34(29):3562-3569
pubmed: 27528724
Biomark Res. 2020 Sep 29;8:49
pubmed: 33005420
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):1939-1943
pubmed: 31350948
Annu Rev Immunol. 2018 Apr 26;36:411-433
pubmed: 29677473
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31611251
Tumour Biol. 2015 Dec;36(12):9159-70
pubmed: 26088449
Hum Immunol. 2016 May;77(5):418-25
pubmed: 27006334
Blood Cancer J. 2017 Jun 30;7(6):e577
pubmed: 28665419
Medicine (Baltimore). 2020 Oct 30;99(44):e23006
pubmed: 33126384
Genet Test Mol Biomarkers. 2014 Jun;18(6):403-9
pubmed: 24819026
Biochem Med (Zagreb). 2015;25(1):36-48
pubmed: 25672465
Pharmgenomics Pers Med. 2022 Mar 15;15:227-234
pubmed: 35313604
PLoS One. 2016 Jul 20;11(7):e0159115
pubmed: 27438131
Sci Rep. 2015 Nov 27;5:17149
pubmed: 26612133
PLoS One. 2021 Mar 8;16(3):e0248259
pubmed: 33684151
Haematologica. 2007 Nov;92(11):1475-81
pubmed: 18024395
Blood. 2004 May 1;103(9):3529-34
pubmed: 14701701